Sionna Therapeutics (NASDAQ:SION) Trading 6.5% Higher – Here’s What Happened

Sionna Therapeutics, Inc. (NASDAQ:SION)’s share price traded up 6.5% during mid-day trading on Tuesday . The stock traded as high as $40.43 and last traded at $41.3360. Approximately 97,874 shares were traded during mid-day trading, a decline of 72% from the average daily volume of 349,595 shares. The stock had previously closed at $38.83.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on SION shares. Wall Street Zen cut Sionna Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. JonesTrading lifted their target price on Sionna Therapeutics from $52.00 to $63.00 and gave the stock a “buy” rating in a report on Tuesday, April 28th. Freedom Capital lowered Sionna Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, May 20th. UBS Group reaffirmed a “buy” rating on shares of Sionna Therapeutics in a report on Monday, March 2nd. Finally, Citizens Jmp reiterated a “market outperform” rating and issued a $63.00 price target on shares of Sionna Therapeutics in a research report on Tuesday, May 26th. Three equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Sionna Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $53.22.

Sionna Therapeutics Price Performance

The firm has a market cap of $1.89 billion, a price-to-earnings ratio of -21.59 and a beta of 1.30. The stock’s fifty day moving average price is $39.89 and its 200-day moving average price is $39.44.

Sionna Therapeutics (NASDAQ:SION) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.60) EPS for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.08). As a group, equities research analysts predict that Sionna Therapeutics, Inc. will post -2.57 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Orbimed Advisors Llc sold 184,639 shares of the firm’s stock in a transaction on Monday, May 11th. The stock was sold at an average price of $46.22, for a total value of $8,534,014.58. Following the completion of the sale, the director owned 2,671,822 shares of the company’s stock, valued at $123,491,612.84. This trade represents a 6.46% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Peter A. Thompson sold 184,639 shares of Sionna Therapeutics stock in a transaction on Monday, May 11th. The shares were sold at an average price of $46.22, for a total value of $8,534,014.58. Following the transaction, the director owned 2,671,822 shares in the company, valued at $123,491,612.84. This represents a 6.46% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 1,717,962 shares of company stock valued at $77,571,889 in the last 90 days. Corporate insiders own 5.10% of the company’s stock.

Hedge Funds Weigh In On Sionna Therapeutics

Large investors have recently made changes to their positions in the business. Eventide Asset Management LLC purchased a new stake in shares of Sionna Therapeutics in the fourth quarter worth approximately $26,290,000. Vanguard Group Inc. increased its stake in Sionna Therapeutics by 81.4% in the 3rd quarter. Vanguard Group Inc. now owns 1,143,154 shares of the company’s stock valued at $33,620,000 after buying an additional 512,803 shares during the period. State Street Corp increased its stake in Sionna Therapeutics by 188.7% in the 4th quarter. State Street Corp now owns 693,395 shares of the company’s stock valued at $28,526,000 after buying an additional 453,196 shares during the period. Jennison Associates LLC lifted its position in Sionna Therapeutics by 30.1% in the 1st quarter. Jennison Associates LLC now owns 1,451,220 shares of the company’s stock worth $58,179,000 after buying an additional 335,942 shares in the last quarter. Finally, Viking Global Investors LP lifted its position in Sionna Therapeutics by 8.2% in the 2nd quarter. Viking Global Investors LP now owns 3,195,181 shares of the company’s stock worth $55,436,000 after buying an additional 242,427 shares in the last quarter.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.